It takes the average reader and 4 minutes to read The Case of Synthroid (A) by Alice M. Tybout
Assuming a reading speed of 250 words per minute. Learn more
The case tells the story of Synthroid from its development in 1958 as the first synthetic thyroxine molecule to its competition against generic equivalents in 2004. The case introduces students to the pharmaceutical industry, its practices, and some of the complexities of pricing and drug choice, with drug manufacturers, insurance companies, physicians, pharmacists, and patients all playing a role. It also provides a primer on hypothyroidism, its symptoms, and its treatment. Because Synthroid was developed and introduced before FDA regulations and drug standards of identity were fully established, it was difficult for competitors to get their drugs certified as identical to Synthroid. Through a series of efforts with physicians, especially endocrinologists, Synthroid's owners were able to maintain the perception for forty-six years that Synthroid was uniquely effective. In 2004, however, the FDA declared several competitive products to be bioequivalent to Synthroid, which posed a significant challenge to its owner, Abbott Laboratories. Students are challenged to consider options to maintain the drug's unit volume, revenue, and/or profit in these difficult circumstances. The case is written in two parts. The (A) case provides background on the history of the drug, the pharmaceutical industry and its marketing practices, and hypothyroidism and its treatment, and it concludes in 2004 as Abbott's marketers face the impending challenge of defending the Synthroid business against generic competition. The (B) case describes what Abbott actually did to maintain its share in the United States and outlines its strategy in India, a market without patent protection for pharmaceuticals. After analyzing the case students should be able to: - Describe strategies that branded competitors can use to defend their business from lower-priced competition - Understand the basics of pharmaceutical marketing and pricing, including the global challenge of defending branded drugs against generic equivalents - Discuss ethical issues in the marketing of high-margin branded products that have lower-priced alternatives, especially in the healthcare industry.
The Case of Synthroid (A) by Alice M. Tybout is 4 pages long, and a total of 1,016 words.
This makes it 1% the length of the average book. It also has 1% more words than the average book.
The average oral reading speed is 183 words per minute. This means it takes and 5 minutes to read The Case of Synthroid (A) aloud.
The Case of Synthroid (A) is suitable for students ages 6 and up.
Note that there may be other factors that effect this rating besides length that are not factored in on this page. This may include things like complex language or sensitive topics not suitable for students of certain ages.
When deciding what to show young students always use your best judgement and consult a professional.
The Case of Synthroid (A) by Alice M. Tybout is sold by several retailers and bookshops. However, Read Time works with Amazon to provide an easier way to purchase books.
To buy The Case of Synthroid (A) by Alice M. Tybout on Amazon click the button below.
Buy The Case of Synthroid (A) on Amazon